Cara J Westmark


Affiliation: University of Wisconsin
Country: USA


  1. Westmark C. Fragile X and APP: a Decade in Review, a Vision for the Future. Mol Neurobiol. 2018;: pubmed publisher
  2. Westmark C, Westmark P, Malter J. Soy-based diet exacerbates seizures in mouse models of neurological disease. J Alzheimers Dis. 2013;33:797-805 pubmed publisher
    ..Thus, the soy isoflavone daidzein recapitulated seizure induction in vivo and altered A?PP expression in vitro. These results have important implications for individuals on soy-based diets as well as for rodent model research. ..
  3. Westmark P, Dekundy A, Gravius A, Danysz W, Westmark C. Rescue of Fmr1KO phenotypes with mGluR5 inhibitors: MRZ-8456 versus AFQ-056. Neurobiol Dis. 2018;119:190-198 pubmed publisher
  4. Westmark C, Westmark P, Malter J. Alzheimer's disease and Down syndrome rodent models exhibit audiogenic seizures. J Alzheimers Dis. 2010;20:1009-13 pubmed publisher
    ..Our data strongly implicates AbetaPP or a catabolite in seizure susceptibility and suggests that mGluR5 mediates this response. ..
  5. Westmark C. The quest for fragile X biomarkers. Mol Cell Pediatr. 2014;1:1 pubmed publisher
    ..Bench-to-bedside plans for fragile X syndrome are severely limited by the lack of validated outcome measures. The reviewed candidate biomarkers are at early stages of validation and deserve further investigation. ..
  6. Westmark C. What's hAPPening at synapses? The role of amyloid ?-protein precursor and ?-amyloid in neurological disorders. Mol Psychiatry. 2013;18:425-34 pubmed publisher
  7. Westmark C, Westmark P, Malter J. MPEP reduces seizure severity in Fmr-1 KO mice over expressing human Abeta. Int J Clin Exp Pathol. 2009;3:56-68 pubmed
    ..These data suggest that Abeta contributes to seizure incidence and may be an appropriate therapeutic target to lessen seizure pathology in FXS, Alzheimer's disease (AD) and Down syndrome (DS) patients. ..
  8. Westmark C, Westmark P, O Riordan K, Ray B, Hervey C, Salamat M, et al. Reversal of fragile X phenotypes by manipulation of A?PP/A? levels in Fmr1KO mice. PLoS ONE. 2011;6:e26549 pubmed publisher
    ..Evolving therapies directed at reducing A? in AD may be applicable to FXS and A? may serve as a plasma-based biomarker to facilitate disease diagnosis or assess therapeutic efficacy...
  9. Westmark C, Malter J. The regulation of A?PP expression by RNA-binding proteins. Ageing Res Rev. 2012;11:450-9 pubmed publisher